Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00015834 · ClinicalTrials.gov registry record · Phase 1
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase 1 study of Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Blastic Phase Chronic Myelogenous Leukemia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT00015834: Completed Phase 1 study of Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Blastic Phase Chronic Myelogenous Leukemia, sponsored by National Cancer Institute (NCI).
NCT00015834 is a Phase 1 study of Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Blastic Phase Chronic Myelogenous Leukemia that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 46 participants, above the 42-participant average among 10 other Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00015834, a Phase 1 study of Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Blastic Phase Chronic Myelogenous Leukemia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I/II trial to study the effectiveness of combining STI571 and chemotherapy in treating patients who have chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. STI571 may stop the growth of leukemia cells. Combining chemotherapy and STI571 may kill more cancer cells
Primary Outcome
Described by duration, relatedness to treatment, and action taken.
Conditions Studied
Interventions
- DRUG imatinib mesylate
- DRUG cytarabine
Study Locations (1)
California
- University of California at Los Angeles (UCLA ) - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2001-05 |
| Phase | Phase 1 |
What the finished NCT00015834 record still lists
NCT00015834 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, above the 42-participant average among 10 other Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials with a reported enrollment target (10% higher).
The record links to 3 conditions, with Chronic Myelogenous Leukemia, BCR-ABL1 Positive appearing as the primary indexed condition, and to 2 interventions - of which imatinib mesylate is the first listed.
NCT00015834 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00015834 about?
NCT00015834 is a clinical study titled "STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia". Phase I/II trial to study the effectiveness of combining STI571 and chemotherapy in treating patients who have chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. STI571 may stop the growth of leukemia cells. Com...
What is the current status of trial NCT00015834?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2001-05.
What conditions does trial NCT00015834 study?
This clinical trial studies the following conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blastic Phase Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia.
What interventions are being tested in trial NCT00015834?
The interventions under investigation include: imatinib mesylate (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00015834?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00015834 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00015834's enrollment target sits among peer trials
46 6th of 10 higher than 5 of 10 other Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
RECRUITING · Phase 1
-
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
COMPLETED · Phase 1
-
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
COMPLETED · Phase 1
-
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
ACTIVE NOT RECRUITING · Phase 2
-
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia